[Paper-level Aggregated] PMCID: PMC2360265

Evidence Type(s): Oncogenic

Summary: Mutation: E746V | Summary: The E746V mutation is identified as a classical mutation in patients, suggesting its contribution to tumor development or progression due to its somatic origin.

Evidence Type: Oncogenic Mutation: G719D | Summary: The G719D mutation is classified as a classical mutation in patients, indicating its role in tumor development or progression as it is of somatic origin.

Evidence Type: Oncogenic Mutation: L858R | Summary: The L858R mutation is noted as a classical point mutation in patients, supporting its involvement in tumor development or progression due to its somatic nature. It is particularly associated with adenocarcinomas and smoking status.

Gene→Variant (gene-first): EGFR(1956):E746V EGFR(1956):G719D EGFR(1956):L858R

Genes: EGFR(1956)

Variants: E746V G719D L858R

[Paper-level Aggregated] PMCID: PMC2360265

Evidence Type(s): Prognostic

Summary: Mutation: L858R | Summary: The L858R mutation is associated with time to tumor progression (TTP), indicating its potential role in influencing disease outcome independent of therapy. However, the difference in TTP compared to other mutations did not reach statistical significance. Additionally, when analyzed in relation to overall survival (OS), no statistically significant difference in OS was found when compared to patients with the DEL19 mutation.

Gene→Variant (gene-first): EGFR(1956):L858R

Genes: EGFR(1956)

Variants: L858R

[Paper-level Aggregated] PMCID: PMC2360265

Evidence Type(s): Diagnostic

Summary: Mutation: L858R | Summary: The presence of the L858R mutation is used to classify patients within the 'classical mutations' group, indicating its role in defining or confirming a subtype of disease.

Gene→Variant (gene-first): EGFR(1956):L858R

Genes: EGFR(1956)

Variants: L858R

[Paper-level Aggregated] PMCID: PMC2360265

Evidence Type(s): Predictive

Summary: Mutation: G719X | Summary: The G719X mutation has been associated with sensitivity to tyrosine kinase inhibitors (TKIs) in patients with NSCLC.

Evidence Type: Predictive Mutation: L858R | Summary: The L858R mutation has been associated with sensitivity to tyrosine kinase inhibitors (TKIs) in patients with NSCLC and is associated with disease control, as two out of three patients with this mutation experienced disease control (one with PR and one with SD).

Evidence Type: Predictive Mutation: G719D | Summary: The G719D mutation is associated with disease control, as both patients with this mutation achieved stable disease (SD).

Evidence Type: Predictive Mutation: E746V | Summary: The E746V mutation is associated with disease control, as both patients with this mutation achieved stable disease (SD).

Gene→Variant (gene-first): EGFR(1956):G719X EGFR(1956):L858R EGFR(1956):G719D EGFR(1956):E746V

Genes: EGFR(1956)

Variants: G719X L858R G719D E746V

[Paragraph-level] PMCID: PMC2360265 Section: RESULTS PassageIndex: 16

Evidence Type(s): Prognostic

Summary: Evidence Type: Prognostic | Mutation: L858R | Summary: The L858R mutation was analyzed in relation to overall survival (OS), but no statistically significant difference in OS was found when compared to patients with the DEL19 mutation.

Gene→Variant (gene-first): 1956:L858R

Genes: 1956

Variants: L858R

[Paragraph-level] PMCID: PMC2360265 Section: RESULTS PassageIndex: 14

Evidence Type(s): Prognostic

Summary: Evidence Type: Prognostic | Mutation: L858R | Summary: The L858R mutation is associated with time to tumor progression (TTP), indicating its potential role in influencing disease outcome independent of therapy. However, the difference in TTP compared to other mutations did not reach statistical significance.

Gene→Variant (gene-first): 1956:L858R

Genes: 1956

Variants: L858R

[Paragraph-level] PMCID: PMC2360265 Section: RESULTS PassageIndex: 12

Evidence Type(s): Predictive

Summary: Evidence Type: Predictive | Mutation: L858R | Summary: The L858R mutation is associated with disease control, as two out of three patients with this mutation experienced disease control (one with PR and one with SD). Evidence Type: Predictive | Mutation: G719D | Summary: The G719D mutation is associated with disease control, as both patients with this mutation achieved stable disease (SD). Evidence Type: Predictive | Mutation: E746V | Summary: The E746V mutation is associated with disease control, as both patients with this mutation achieved stable disease (SD).

Gene→Variant (gene-first): 1956:E746V 1956:G719D 1956:L858R

Genes: 1956

Variants: E746V G719D L858R

[Paragraph-level] PMCID: PMC2360265 Section: RESULTS PassageIndex: 7

Evidence Type(s): Oncogenic, Diagnostic

Summary: Evidence Type: Oncogenic | Mutation: L858R | Summary: The L858R mutation is classified as a 'classical mutation' and is associated with tumor development or progression in patients, particularly in the context of adenocarcinomas and smoking status. Evidence Type: Diagnostic | Mutation: L858R | Summary: The presence of the L858R mutation is used to classify patients within the 'classical mutations' group, indicating its role in defining or confirming a subtype of disease.

Gene→Variant (gene-first): 1956:L858R

Genes: 1956

Variants: L858R

[Paragraph-level] PMCID: PMC2360265 Section: RESULTS PassageIndex: 6

Evidence Type(s): Oncogenic

Summary: Evidence Type: Oncogenic | Mutation: E746V | Summary: The E746V mutation is identified as a classical mutation in patients, suggesting its contribution to tumor development or progression due to its somatic origin. Evidence Type: Oncogenic | Mutation: G719D | Summary: The G719D mutation is classified as a classical mutation in patients, indicating its role in tumor development or progression as it is of somatic origin. Evidence Type: Oncogenic | Mutation: L858R | Summary: The L858R mutation is noted as a classical point mutation in patients, supporting its involvement in tumor development or progression due to its somatic nature.

Gene→Variant (gene-first): 1956:E746V 1956:G719D 1956:L858R

Genes: 1956

Variants: E746V G719D L858R

[Paragraph-level] PMCID: PMC2360265 Section: ABSTRACT PassageIndex: 1

Evidence Type(s): Predictive

Summary: Evidence Type: Predictive | Mutation: G719X | Summary: The G719X mutation has been associated with sensitivity to tyrosine kinase inhibitors (TKIs) in patients with NSCLC. Evidence Type: Predictive | Mutation: L858R | Summary: The L858R mutation has been associated with sensitivity to tyrosine kinase inhibitors (TKIs) in patients with NSCLC.

Gene→Variant (gene-first): 1956:G719X 1956:L858R

Genes: 1956

Variants: G719X L858R

[Paper-level Aggregated] PMCID: PMC2360265

Evidence Type(s): Predictive, Oncogenic, Prognostic

Justification: Predictive: The text indicates that classical mutations in the EGFR tyrosine kinase domain are associated with sensitivity to tyrosine kinase inhibitors (TKIs) in patients with NSCLC, suggesting that these mutations can predict treatment response. Oncogenic: The presence of EGFR mutations, including E746V, G719D, and L858R, is implied to have a role in tumorigenesis, as they are described as somatic mutations found in tumor tissues, indicating their potential oncogenic nature. Prognostic: The text discusses median time to tumor progression (TTP) and overall survival (OS) in relation to different EGFR mutation statuses, suggesting that these mutations may have prognostic implications for patient outcomes.

Gene→Variant (gene-first): EGFR(1956):E746V EGFR(1956):G719D EGFR(1956):L858R EGFR(1956):G719X

Genes: EGFR(1956)

Variants: E746V G719D L858R G719X

[Paragraph-level] PMCID: PMC2360265 Section: RESULTS PassageIndex: 16

Evidence Type(s): Prognostic, Diagnostic

Justification: Prognostic: The passage discusses median overall survival (OS) in relation to the L858R mutation, indicating that there is no statistically significant difference in OS between patients with the L858R mutation and those with other mutations, which relates to disease outcome. Diagnostic: The mention of the L858R mutation in the context of comparing survival outcomes suggests its role in classifying or defining patient subgroups based on mutational status.

Gene→Variant (gene-first): 1956:L858R

Genes: 1956

Variants: L858R

[Paragraph-level] PMCID: PMC2360265 Section: RESULTS PassageIndex: 14

Evidence Type(s): Prognostic, Diagnostic

Justification: Prognostic: The passage discusses time to tumor progression (TTP) in relation to different mutation groups, including L858R, indicating a correlation with disease outcome independent of therapy. Diagnostic: The mention of "classical mutations group" and comparisons with "wild-type" suggests that the L858R variant is used to classify or define a subtype of the disease.

Gene→Variant (gene-first): 1956:L858R

Genes: 1956

Variants: L858R

[Paragraph-level] PMCID: PMC2360265 Section: RESULTS PassageIndex: 12

Evidence Type(s): Predictive, Diagnostic

Justification: Predictive: The passage discusses the disease control rate (DCR) in relation to specific mutations, indicating a correlation between the presence of mutations (including L858R, G719D, and E746V) and treatment outcomes, which suggests predictive evidence regarding therapy response. Diagnostic: The mention of 'classical' mutations and their association with disease control rates implies that these mutations, including L858R, G719D, and E746V, are used to classify or define a subtype of the disease.

Gene→Variant (gene-first): 1956:E746V 1956:G719D 1956:L858R

Genes: 1956

Variants: E746V G719D L858R

[Paragraph-level] PMCID: PMC2360265 Section: RESULTS PassageIndex: 7

Evidence Type(s): Diagnostic, Oncogenic

Justification: Diagnostic: The passage discusses the incidence of the L858R mutation in relation to patient demographics and histology, indicating its association with specific patient groups and suggesting its role in defining or classifying disease subtypes. Oncogenic: The mention of the L858R mutation in the context of 'classical mutations' and its presence in patients with tumors suggests that it contributes to tumor development or progression.

Gene→Variant (gene-first): 1956:L858R

Genes: 1956

Variants: L858R

[Paragraph-level] PMCID: PMC2360265 Section: RESULTS PassageIndex: 6

Evidence Type(s): Diagnostic, Oncogenic

Justification: Diagnostic: The passage discusses the identification of patient groups based on their mutational status, specifically mentioning the presence of classical mutations such as G719D, E746V, and L858R, which are used to classify patients. Oncogenic: The passage indicates that the reported EGFR mutations, including G719D, E746V, and L858R, were found to be of somatic origin, suggesting their contribution to tumor development or progression.

Gene→Variant (gene-first): 1956:E746V 1956:G719D 1956:L858R

Genes: 1956

Variants: E746V G719D L858R

[Paragraph-level] PMCID: PMC2360265 Section: ABSTRACT PassageIndex: 1

Evidence Type(s): Predictive, Diagnostic

Justification: Predictive: The passage discusses the association of classical mutations, including G719X and L858R, with sensitivity to tyrosine kinase inhibitors (TKIs) in patients with NSCLC, indicating a correlation with treatment response. Diagnostic: The mention of classical mutations in the EGFR tyrosine kinase domain being associated with sensitivity to TKIs suggests that these variants can be used to classify or define a subtype of disease in NSCLC patients.

Gene→Variant (gene-first): 1956:G719X 1956:L858R

Genes: 1956

Variants: G719X L858R

[Paragraph-level] PMCID: PMC2360265 Section: RESULTS PassageIndex: 16

Evidence Type(s): Prognostic, Diagnostic

Justification: Prognostic: The passage discusses median overall survival (OS) in relation to the L858R mutation, indicating that there is no statistically significant difference in OS between patients with the L858R mutation and those with other mutations, which relates to disease outcome. Diagnostic: The mention of the L858R mutation in the context of comparing survival outcomes suggests its role in classifying or defining patient subgroups based on mutational status.

Gene→Variant (gene-first): 1956:L858R

Genes: 1956

Variants: L858R

[Paragraph-level] PMCID: PMC2360265 Section: RESULTS PassageIndex: 14

Evidence Type(s): Prognostic, Diagnostic

Justification: Prognostic: The passage discusses time to tumor progression (TTP) in relation to different mutation groups, including L858R, indicating a correlation with disease outcome independent of therapy. Diagnostic: The mention of "classical mutations group" and comparisons with "wild-type" suggests that the L858R variant is used to classify or define a subtype of the disease.

Gene→Variant (gene-first): 1956:L858R

Genes: 1956

Variants: L858R

[Paragraph-level] PMCID: PMC2360265 Section: RESULTS PassageIndex: 12

Evidence Type(s): Predictive, Diagnostic

Justification: Predictive: The passage discusses the disease control rate (DCR) in relation to specific mutations, indicating a correlation between the presence of mutations (including L858R, G719D, and E746V) and treatment outcomes, which suggests predictive evidence regarding therapy response. Diagnostic: The mention of 'classical' mutations and their association with disease control rates implies that these mutations, including L858R, G719D, and E746V, are used to classify or define a subtype of the disease.

Gene→Variant (gene-first): 1956:E746V 1956:G719D 1956:L858R

Genes: 1956

Variants: E746V G719D L858R

[Paragraph-level] PMCID: PMC2360265 Section: RESULTS PassageIndex: 7

Evidence Type(s): Diagnostic, Oncogenic

Justification: Diagnostic: The passage discusses the incidence of the L858R mutation in relation to patient demographics and histology, indicating its association with specific patient groups and suggesting its role in defining or classifying disease subtypes. Oncogenic: The mention of the L858R mutation in the context of 'classical mutations' and its presence in patients with tumors suggests that it contributes to tumor development or progression.

Gene→Variant (gene-first): 1956:L858R

Genes: 1956

Variants: L858R

[Paragraph-level] PMCID: PMC2360265 Section: RESULTS PassageIndex: 6

Evidence Type(s): Diagnostic, Oncogenic

Justification: Diagnostic: The passage discusses the identification of patient groups based on their mutational status, specifically mentioning the presence of classical mutations such as G719D, E746V, and L858R, which are used to classify patients. Oncogenic: The passage indicates that the reported EGFR mutations, including G719D, E746V, and L858R, were found to be of somatic origin, suggesting their contribution to tumor development or progression.

Gene→Variant (gene-first): 1956:E746V 1956:G719D 1956:L858R

Genes: 1956

Variants: E746V G719D L858R

[Paragraph-level] PMCID: PMC2360265 Section: ABSTRACT PassageIndex: 1

Evidence Type(s): Predictive, Diagnostic

Justification: Predictive: The passage discusses the association of classical mutations, including G719X and L858R, with sensitivity to tyrosine kinase inhibitors (TKIs) in patients with NSCLC, indicating a correlation with treatment response. Diagnostic: The mention of classical mutations in the EGFR tyrosine kinase domain being associated with sensitivity to TKIs suggests that these variants can be used to classify or define a subtype of disease in NSCLC patients.

Gene→Variant (gene-first): 1956:G719X 1956:L858R

Genes: 1956

Variants: G719X L858R